|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG008503141 |
| 003 |
DE-627 |
| 005 |
20230605130932.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
220609s2023 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG008503141
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)TCTR20220516002
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)Nil Known
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Immunogenicity and Safety Outcome of Homologous and Heterologous Prime-boost of Inactivated Vaccine and Replication-defective Viral Vectors Vaccine Against SARS-CoV2 among Hemodialysis Patients: An Observational Prospective Cohort Trial
|b Immunogenicity and Safety Outcome of Homologous and Heterologous Prime-boost of Inactivated Vaccine and Replication-defective Viral Vectors Vaccine Against SARS-CoV2 among Hemodialysis Patients: An Observational Prospective Cohort Trial
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 16-05-2022, Last updated: 2023-06-05
|
| 650 |
|
4 |
|a Medical Condition: An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was dispersed in many countries, which subsequently resulting in global pandemic. According to the contagious and virulence profile of this virus, it was contributed to high morbidity and mortality among patients who were infected. The risk of mortality from COVID-19 disease appears to be higher in patients with aged over 70 years old, taking immunosuppressive agents and whom with pre-existing medical comorbidities including chronic kidney disease (CKD).Vaccines to prevent SARS-CoV-2 infection are considered as the most promising approach for modulating the pandemic and are being vigorously pursued. Many of those have received emergency use through the supporting evidence from the standard hierarchically developmental studies. Unfortunately, patients with kidney disease (including on dialysis, or with a kidney transplant) were generally excluded from those clinical trials.Therefore, it is unknown that those vaccines are effectual in patients with kidney disease as demonstrated in those healthy people, since a potential diminished immune response in individuals who are immunocompromised as a result of their disease or treatment. Therefore, the data of current available COVID-19 vaccines in term of efficacy and safety among patients with kidney disease are still limited. SARS-CoV-2, COVID-19, inactivated vaccine, replication defective viral vectors vaccine, vaccine immunogenicity, hemodialysis;SARS-CoV-2, COVID-19, inactivated vaccine, replication defective viral vectors vaccine, vaccine immunogenicity, hemodialysis
|
| 650 |
|
4 |
|a Study Type: Observational
|
| 650 |
|
4 |
|a Recruitment Status: Completed
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 29. Mai
|
| 773 |
1 |
8 |
|g year:2023
|g day:29
|g month:05
|
| 856 |
4 |
0 |
|u https://www.thaiclinicaltrials.org/show/TCTR20220516002
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 29
|c 05
|
Klinische Studie